Buscar
Mostrando ítems 1-7 de 7
Advances in hepatitis B therapeutics
(Therapeutic Advances in Infectious Disease, 2020-10)
Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of ...
Envisioning a hepatitis delta cure with new antivirals
(Future Medicine Ltd., 2021)
Envisioning a hepatitis delta cure with new antivirals
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain
(Hepatology International, 2022)
Background: Chronic viral hepatitis B, C, and D are the main causes of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented more than 2 decades ago in most EU countries. Furthermore, ...
Viral hepatitis in persons living with HIV in the post-COVID era
(AIDS reviews, 2023)
Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly produce acute self-limited episodes ...
Envisioning hepatitis delta cure without functional hepatitis B cure
(AIDS reviews, 2022)
[abstract not available]
Treatment of hepatitis delta and HIV infection
(Liver International, 2023)
Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5–10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15–25 million ...
Triple Threat: HDV, HBV, HIV Coinfection
(Clinics in Liver Disease, 2023)
First discovered in the late 1970s, hepatitis delta virus (HDV) has emerged as an important driver of decompensated liver disease and hepatocellular carcinoma (HCC) worldwide. HDV requires hepatitis B virus (HBV) for ...